Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- The GLP-1 Paradox in Colorectal Cancer (Medscape)
- The most pressing workforce issues for 103 healthcare leaders (Becker’s Healthcare)
- FDA-cleared GI test detects ‘most likely causes’ of diarrheal syndromes (Healio)
- A path forward: women in gastroenterology (Gastrointestinal Endoscopy)
- 5 Gastroenterology Headlines You Missed in February 2026 (HCP Live)
- Endoluminal Robotics – what it really is (How to Startup in MedTech)
- AI in GI: A Humanist Approach (GI & Endoscopy News)
- Gastroenterology and private equity in 2026: 5 notes (Becker’s GI & Endoscopy)
